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Introduction
Allogeneic hematopoietic stem cell transplantation (HSCT) can cure many hematological malignancies, although graft-versus-host disease (GVHD) and relapse remain significant obstacles. The efficacy of HSCT results from cytotoxic conditioning and a graft-versus-leukemia (GVL) effect (1, 2) . Myeloablative conditioning regimens that employ total body irradiation and/or intensive chemotherapy exhibit potent antitumor activity, but are limited to young patients due to nonhematopoietic toxicities. Allogeneic HSCT can be extended to older patients and those with comorbidities using reduced intensity nonmyeloablative conditioning regimens that provide less antitumor activity but immunosuppress the recipient sufficiently to allow engraftment of donor hematopoietic cells and enable a GVL effect (3) (4) (5) (6) (7) . Nonmyeloablative HSCT (NM-HSCT) leads to remission in a subset of patients with refractory indolent hematologic malignancies including chronic lymphocytic leukemia (CLL) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . The eradication of CLL after NM-HSCT is associated with GVHD, and presumed to be a consequence of T cell recognition of alloantigens expressed by leukemic cells (18) . However, many patients do not respond to NM-HSCT despite developing GVHD and others respond without significant GVHD. Thus, the basis for a successful GVL effect remains poorly defined in individual patients.
CLL is amenable to studies of the GVL effect because leukemia cells can be obtained from most patients, and induced to become efficient antigen presenting cells (APC) by stimulation through CD40 (19) (20) (21) . Here, we used recipient CD40L stimulated CLL as APC to isolate donor T cells that were specific for CLL after NM-HSCT. CD8
+ and CD4 + T cells that recognized multiple minor H antigens expressed on recipient CLL were isolated from all patients CLL-REACTIVE T CELL RESPONSES AFTER STEM CELL TRANSPLANT 6 who achieved or maintained a complete remission (CR) after NM-HSCT. In addition, CD8 + T cell clones that recognized recipient CLL but not EBV-transformed B cells were isolated from responding patients, suggesting a component of the response is directed against tumor-specific determinants. Despite the development of GVHD and high levels of donor T cell chimerism, CLL-specific T cells were not detected in recipients with persistent or progressive leukemia.
These results demonstrate that the specificities of the T cell responses that develop after allogeneic NM-HSCT are critical in determining antitumor efficacy, and illustrate the potential to manipulate T cell reactivity to target antigens expressed selectively by tumor cells to improve outcome.
Materials and Methods

Patient and Donor Eligibility
Patients with CLL who failed to meet National Cancer Institute (NCI) Working Group
Criteria for complete or partial response (22) after therapy with a regimen containing fludarabine, or who relapsed within 12 months after completing fludarabine, and had an HLA-A, -B, -C, -DRB1, and -DQB1 matched related or unrelated donor were eligible. Exclusion criteria included central nervous system involvement, history of malignancy other than CLL within the past 5 years, Karnofsky score less than 60%, and severe cardiovascular, pulmonary, or hepatic dysfunction. Granulocyte colony-stimulating factor (G-CSF) mobilized peripheral blood was the source of stem cells. All patients and their related donors signed consent forms approved by the FHCRC institutional review board. Informed consent was obtained from the unrelated donors CLL-REACTIVE T CELL RESPONSES AFTER STEM CELL TRANSPLANT 7 according to National Marrow Donor Program (NMDP) regulations.
Treatment Plan
Patients were conditioned for transplantation with fludarabine 30 mg/m 2 /day on days -4 to -2, and 200 cGy of total body irradiation on day 0. The patients received immunosuppression with cyclosporine or tacrolimus given orally every 12 hours beginning on day -3; and mycophenolate mofetil given beginning on day 0 every 12 hours to recipients with related donors, and every 8 hours to recipients with unrelated donors (16 
Disease Response and GVHD Assessment
Disease response was assessed using NCI Working Group Criteria (22) . Patients underwent evaluation for minimal residual CLL by flow cytometry of peripheral blood and bone marrow. Diagnosis and grading of acute and chronic GVHD were performed according to established criteria (23, 24) .
Cell Lines
Epstein-Barr virus transformed B-cells (B-LCL) were generated from patients and donors as described (25) . B-LCL and CLL from individuals of known HLA types were used as targets to determine the HLA-restricting allele and the frequency of individual minor H or CLL-REACTIVE T CELL RESPONSES AFTER STEM CELL TRANSPLANT 8 tumor-associated antigens. Fibroblast cell lines were generated and maintained as described (25) .
Isolation of CLL-Reactive T Cell Lines and Clones
PBMC were isolated by centrifugation over Ficoll-Hypaque and cryopreserved. NIH 3T3 cells transfected with human CD40L (tCD40L) were a gift of Dr. J. Schultze and used to generate CD40 activated CLL cells (CD40-CLL) as described (26) . After 3 days of activation, an aliquot of cells was analyzed for expression of CD5, CD19, HLA-class I, HLA-class II, CD80, CD86, CD54 and CD58 to determine purity and confirm activation through CD40. A second aliquot of CD40-CLL was γ-irradiated and used as APC to stimulate post-transplant PBMC.
When further expansion of CLL cells was required, CD40-CLL were transferred to fresh tCD40L every 3-4 days.
To generate T cell lines, PBMC (3x10 6 /well) obtained from the recipient at intervals post-transplant were stimulated with γ-irradiated (35 Gy) recipient CD40-CLL (0.75 x10 6 /well) in RPMI, 10% human serum, 2 mM L-glutamine and 1% penicillin-streptomycin. Cultures were restimulated after seven days with γ-irradiated recipient CD40-CLL at a responder to stimulator ratio of 4:1. The medium was supplemented with IL-7 (10 ng/mL on day 0 of each stimulation) and IL-2 (2 U/mL) on day 3 after the first stimulation, and then 10 U/mL on days 1 and 4 of the second stimulation. After 2 weeks, T cell lines were tested for cytotoxic activity against recipient-and donor-derived B-LCL and recipient CD40-CLL.
CD8
+ and CD4 + T cells that secreted IFN-γ after stimulation with CD40-CLL were sort-purified using IFN-γ capture. An aliquot (1x10 6 cells) of each of the T cell lines was co-cultured with CD40-CLL (1-2 x 10 6 ) in media containing 20 U/ml IL-2 at 37℃ for 4 hours and then processed as described (27, 28 
Flow cytometry
T cells, primary CLL and CD40-CLL were stained with one or more of the following monoclonal antibodies conjugated with fluorescein isothiocyanate (FITC) or phycoerythrin (PE):
CD3, CD4, CD5, CD8, CD19, CD40, CD54, CD58, CD80, CD86, HLA-class I, HLA-DR and isotype matched control antibodies (BD Pharmingen). Flow cytometric analysis was performed on a FACSCalibur, and data were analyzed using CellQuest software (Becton Dickinson).
Results
Patient characteristics and clinical outcomes after allogeneic NM-HSCT.
The characteristics of twelve patients treated with NM-HSCT from HLA matched donors are shown in Table 1 has an ongoing partial remission (PR) with a reduction in bone marrow tumor burden from 70% pre transplant to 5% at six months after transplant. Six of these eight patients with a major antitumor response developed acute GVHD and five developed extensive chronic GVHD. Four patients had persistent or progressive CLL after NM-HSCT, despite the administration of DLI to one of these patients (UPN 28196). All four non-responding patients developed acute GVHD, and one of three that survived beyond day 100 developed chronic GVHD. One of the non-responding patients remains alive with persistent CLL. There was no difference in the immunosuppressive therapy regimens used for GVHD prophylaxis between responding and non-responding patients.
Generation of CLL-reactive T cells from post-transplant PBMC
We hypothesized that donor cell engraftment might result in the development of a T cell response specific for recipient minor H or tumor-associated antigens on CLL and contribute to tumor regression. Aliquots of recipient CLL that were cryopreserved pre-transplant were used to stimulate T cells obtained from the recipient post-transplant after donor engraftment was established. CLL expresses class I and II MHC molecules and can be recognized by CD8 + and CD4 + T cells, but has low levels of costimulatory and adhesion molecules (19, 20) . Engagement of CD40 on CLL with CD40 ligand (CD40L) upregulates the expression of co-stimulatory (CD80 and CD86), adhesion (CD54 and CD58) and MHC molecules and makes the tumor cells more efficient APC (19, 20, 26) . Therefore, we co-cultured the pre-transplant CLL from the eleven patients with a high tumor burden with tCD40L prior to their use in vitro for stimulating post-transplant T cells. The frequency of CLL cells in the cultures after CD40L activation was 30.1-97.4% (median 80%) as assessed by co-expression of CD5 and CD19. In the patient in morphologic CR prior to HSCT, we expanded CD5 + CD19 + CLL cells from bone marrow cells after multiple stimulations with tCD40L and used these cells as APC. CLL activated through CD40 expressed higher levels of co-stimulatory, adhesion, and MHC molecules as previously reported (data not shown) (19, 20, 26) .
PBMC were obtained from each recipient at intervals after HSCT, stimulated twice one week apart with γ-irradiated recipient CD40-CLL, and then evaluated for lysis of recipient CD40-CLL, and recipient and donor B-LCL. CD40-CLL rather than thawed primary CLL cells were used as target cells in these experiments because CD40-CLL were of higher purity and exhibited improved viability and uptake of 51 Cr. Cytotoxic T lymphocytes (CTL) that recognized both recipient CLL and B-LCL, but not donor B-LCL were detected after two stimulations at one or more time points from all seven patients with a CR after HSCT or DLI, and from the one patient with a major partial response at six months after HSCT ( Figure 1A) . Figure 1A ). All four of the patients who did not achieve CR after transplantation lacked specific cytotoxicity for recipient CLL at any of the time points analyzed (Figure 1B) , despite the occurrence of GVHD in all patients and >90% donor CD3 T cell chimerism in three of the four patients.
The development of GVHD in the non-responding patients indicates that alloreactive T cells must be present in these patients, but our assays suggest the alloreactivity was not directed against antigens on malignant cells. An alternative explanation is that there was a defect in APC function of the CLL cells from the nonresponding patients. To address this possibility, we evaluated the ability of CD40-CLL from the four non-responding patients and one responding patient to elicit alloreactive T cells in a mixed lymphocyte culture using T cells from an MHC disparate unrelated donor. We found that the CLL from the non-responding patients were equivalently effective APC (Figure 2A, B) . Additionally, a non-responding patient (UPN 28196) and a responding patient (UPN 22388) were both HLA-A2 + males, and the CLL from each of these patients stimulated IFN-γ production from a T cell clone specific for the SMCY minor H antigen (FIDSYICQV) (Figure 2C ). These data demonstrate the failure to detect CLL-reactive T cells in non-responders was not due to lack of APC function by the tumor cells, but rather suggest that the specificity of donor alloreactive T cells that caused GVHD in the recipient was not directed against minor H antigens expressed on recipient CLL.
CD4 + and CD8 + T cells that recognize CLL develop in responding patients
Analysis of the phenotype of the CLL-reactive T cell lines generated from each of the 
Clonal analysis of the CD8 + T cell response to CLL reveals recognition of both minor histocompatibility and tumor-associated antigens.
All of the patients who responded to NM-HSCT also developed GVHD, which is mediated by donor T cells specific for minor H antigens expressed on cells in the skin, gastrointestinal tract, and/or liver (30) (31) (32) . Minor H antigens have previously been identified that are preferentially expressed on hematopoietic cells including B-lineage cells, and recognition of these antigens may be associated with less GVHD (30, (33) (34) (35) . Thus, the isolation of T cell clones from CLL-reactive T cell lines derived from our patients would provide reagents to identify additional minor H antigens that could potentially be targeted to induce a GVL response without GVHD. We focused our efforts on analysis of the CD8 + T cell response because the development of minor H antigen-specific CD8 + T cells after DLI has correlated with tumor regression in other settings (33, 36) , and CD8 + T cells that produced IFN-γ in response to CD40-CLL lysed primary CLL cells more efficiently than CD4 + T cells (Figure 3C, D) .
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We derived CD8 + T cell clones from T cell lines generated at time points that coincided with tumor regression from 7 responding patients. In three patients where adequate numbers of cryopreserved CLL was available, γ-irradiated CLL rather than anti-CD3 monoclonal antibody was used for stimulation in the cloning cultures. In the four patients where tumor cells were limited, cloning wells positive for growth were screened for recognition of recipient and donor B-LCL to identify clones specific for minor H antigens. These T cell clones were subsequently analyzed for recognition of recipient CD40-CLL and fibroblasts to identify minor H antigens that were expressed on tumor cells and preferentially on hematopoietic cells. In the three patients where we had sufficient tumor cells for cloning, we tested each positive well for recognition of recipient CLL and recipient and donor B-LCL to identify T cell clones specific for either minor H or tumor-associated antigens.
Multiple CD8 + T cell clones that recognized a minor H antigen presented by both recipient CD40 CLL and B-LCL, but not donor B-LCL were isolated from all 7 patients (11 for UPN 22388; 10 for UPN 9661; 6 for UPN 21899; 2 for UPN 24487; 12 for UPN 18802; 6 for UPN 28736; 13 for UPN 29449). We attempted to map the HLA-restricting allele for each minor H antigen-specific T cell clone by testing recognition of a panel of B-LCL from unrelated donors that shared only a single HLA allele with the recipient. The restricting HLA allele and an estimate of the allele frequency was determined for 9 minor H antigen-specific T cell clones (Table 2A) . Three of these T cell clones also lysed IFN-γ pre-treated fibroblasts (>10% lysis) demonstrating the expression of the minor H antigen recognized by these T cells was not restricted to hematopoietic cells. Five clones did not lyse fibroblasts and were specific for minor H antigens that are potentially selectively expressed on hematopoietic cells (Table 2A) . We were unable to map the restricting HLA-allele for many of the T cell clones because the panel of partially matched unrelated B-LCL was not sufficient for conclusive assignment. However, based on differential recognition of B-LCL from unrelated donors, we could conclude that the T cell lines from 6 of the 7 patients targeted at least two distinct minor H antigens. Thus, at the time of tumor regression after NM-HSCT, the T cell response was directed against multiple distinct minor H antigens expressed on CLL.
UPN 22388 had a dramatic reduction in circulating tumor cells early after transplant and did not develop GVHD in the first 80 days ( Figure 4A ). Eleven T cell clones were isolated from blood obtained on day 63 and all were restricted by HLA-B40 as shown for clone 2A2 (Table   2A ). These T cell clones did not recognize dermal fibroblasts consistent with the absence of clinical GVHD in this patient at day 63 after HSCT. The patient subsequently developed persistent chronic GVHD at day 120 suggesting that the T cell response might have broadened to include recognition of additional minor H antigens. T cell clones were generated from blood obtained at day 120 and 730 after transplant when the patient had active chronic GVHD, and analysis of the HLA-restricting allele for 9 of these T cell clones revealed recognition of additional distinct minor H antigens presented by HLA-A2, HLA-A31, HLA-B15, HLA-B40 and HLA-Cw3 (Table 2B) . In contrast to the HLA-B40-restricted T cell clone isolated at day 63 that did not recognize fibroblasts, the minor H antigens targeted by 5 of the T cell clones isolated at these later time points were expressed both by CD40 CLL and fibroblasts. One clone (13C6) isolated at day 120 only lysed B-LCL from male HLA-A2 + donors suggesting it was specific for a minor H antigen encoded on the Y-chromosome. Further studies revealed that 13C6 recognized a previously described epitope encoded by the SMCY gene ( Figure 4B, C) , that has been associated with GVHD in prior studies (30) . Of interest, SMCY-specific T cells were not detected in the T cell lines generated at day 63 by tetramer analysis when the patient did not have GVHD, but tetramer binding cells were readily detected in the T cell lines generated from day 120 and 374 samples ( Figure 4D ). These data demonstrate that additional minor H antigen-specific T cells are recruited with time after NM-HSCT, analogous to epitope spreading that has been described in autoimmunity and potentially induced by cytotoxic tumor cell death (37, 38) . The T cell clones that were specific for broadly expressed minor H antigens and isolated late after NM-HSCT, also recognized the recipient's CLL, and may contribute to sustaining the GVL effect (Table 2B ).
The percentage of CD8 + T cells that produced INF-γ was higher after stimulation with CD40-CLL compared to recipient B-LCL in many patients, suggesting that T cells specific for minor H antigens or tumor-associated antigens that are selectively expressed on CLL may be present. In 3 patients in which sufficient tumor cells were available to use both as stimulator cells during cloning and as target cells in screening assays, multiple T cell clones that recognized recipient CLL cells but not B-LCL were identified ( Table 2C ). The proportion of T cell clones that lysed recipient CLL but not B-LCL varied between 30 and 79% of all T cell clones isolated from these patients, suggesting that the tumor-specific response was a significant component of the overall T cell response to CLL. We tested 16 clones obtained from the 3 patients against panels of primary and activated CLL from other patients sharing at least one HLA-allele to
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determine if these T cell clones might be directed against shared and/or non-shared tumor-associated antigens. Twelve of the 16 clones only lysed primary and/or activated CLL from the particular patient they were derived, but not CLL from other patients. Four clones generated from UPN 22388 (14D1, 8A9, 10A10, 30B2) recognized CLL from one or more unrelated patients, however we did not have large enough panels of CLL to conclusively identify the HLA-restricting allele (data not shown). Nevertheless, our data demonstrate that T cells specific for antigens exclusively expressed on CLL but not on B-LCL are elicited after NM-HSCT. These antigens may include non-shared or shared tumor-specific antigens on CLL cells and/or minor H antigens that are only expressed on CLL.
Discussion
NM-HSCT can result in a durable remission for 40-70% of CLL patients who progress after fludarabine based regimens (11, (15) (16) (17) . The efficacy of HSCT in CLL does not correlate with factors that determine outcome after standard chemotherapy and is ascribed to a GVL effect mediated by immune cells in the stem cell graft (9, 10, 13, 14) . Reactivity of T cell lines generated from patients who had persistent or progressive disease after NM-HSCT. and FITC conjugated anti CD8 monoclonal antibodies and an APC conjugated HLA-A*0201
tetramer folded with FIDSYICQV.
